Search This Blog

Tuesday, June 2, 2026

Celcuity Phase 3 shows combinations double PFS vs alpelisib plus fulvestrant in breast cancer

 

Celcuity VIKTORIA-1 Phase 3 shows gedatolisib combinations double progression-free survival vs alpelisib plus fulvestrant in PIK3CA-mutant HR+/HER2- breast cancer

  • Company disclosed pivotal VIKTORIA-1 Phase 3 data in PIK3CA-mutant HR+/HER2- advanced breast cancer via GlobeNewswire and SEC filing.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)